

20th May 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of January 2026 and the end of March 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organisation.

- 1) How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	0
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	122
1.4 Lebrikizumab (Ebglyss)	0
1.5 Mepolizumab (Nucala)	0
1.6 Omalizumab (Xolair)	8
1.7 Reslizumab (Cinqaero)	0
1.8 Tezepelumab (Tezspire)	0

- 2) How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
2.1 Benralizumab (Fasenra)	0	0	0
2.2 Depemokimab (Exdensur)	0	0	0
2.3 Dupilumab (Dupixent)	0	1	0
2.4 Mepolizumab (Nucala)	0	0	0
2.5 Omalizumab (Xolair)	0	0	0
2.6 Reslizumab (Cinqaero)	0	0	0
2.7 Tezepelumab (Tezspire)	0	0	0

- 3) How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number of patients with Atopic Dermatitis
3.1 Dupilumab (Dupixent)	0
3.2 Lebrikizumab (Ebglyss)	0

- 4) How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)	0	0	0
4.2 Depemokimab (Exdensur)	0	0	0
4.3 Dupilumab (Dupixent)	0	114	8
4.4 Lebrikizumab (Ebglyss)	0	0	0
4.5 Mepolizumab (Nucala)	0	0	0
4.6 Omalizumab (Xolair)	0	8	2
4.7 Reslizumab (Cinqaero)	0	0	0
4.8 Tezepelumab (Tezspire)	0	0	0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
 East Sussex Healthcare NHS Trust
 0300 131 4716
 Core Hours of Business: Monday to Friday 9.00am to 4.00pm